Cannabis and Trigeminal Neuralgia
What the evidence actually says about using cannabis for one of the most severe facial pain syndromes known to medicine.
Trigeminal neuralgia (TN) is brutal, and patients understandably try anything — including cannabis. Be honest with yourself: there are no good randomized trials in TN specifically. What exists is a handful of case reports, extrapolation from other neuropathic pain studies, and a lot of patient anecdote. Some people get real relief. Others get nothing, or worse, side effects. Cannabis is not a substitute for carbamazepine, microvascular decompression, or a neurology workup. Treat it as an adjunct to discuss with your neurologist, not a first-line answer.
This is not medical advice
This article summarizes published evidence. It is not a substitute for evaluation by a neurologist or pain specialist. Trigeminal neuralgia can be caused by treatable structural problems (vascular compression, multiple sclerosis lesions, tumors) that require imaging and proper diagnosis. Do not self-treat TN with cannabis instead of getting a workup. If you are already on carbamazepine, oxcarbazepine, or other anticonvulsants, talk to your prescriber before adding cannabis — there are real pharmacokinetic interactions.
Plain-language summary
Trigeminal neuralgia is a chronic pain disorder of the fifth cranial nerve. Classical TN causes sudden, severe, electric-shock-like facial pain, often triggered by light touch, chewing, or wind on the face [1]. First-line medical treatment is carbamazepine or oxcarbazepine; when drugs fail, surgical options include microvascular decompression, gamma knife radiosurgery, and percutaneous rhizotomy [1][2].
Cannabis is not a recognized treatment for TN in any major neurology guideline [1][2]. However, TN patients frequently try it, and cannabinoids have plausible mechanisms in neuropathic pain generally — CB1 and CB2 receptors modulate pain signaling in the trigeminal system in animal models [3]. The honest summary: plausible mechanism, almost no direct human evidence, occasional dramatic anecdotes, and real risks if you use it as a replacement for proven therapy.
What probably works
Nothing in the cannabis category meets a "probably works" bar for trigeminal neuralgia specifically. There are no positive randomized controlled trials of any cannabinoid product in TN No data.
This is a place where the honest answer is uncomfortable. If you want "probably works" for TN, the evidence points to carbamazepine and microvascular decompression in eligible patients [1][2] — not cannabis.
What might work
THC-containing preparations for neuropathic pain (extrapolated). Meta-analyses of cannabinoids in chronic neuropathic pain (mostly HIV neuropathy, diabetic neuropathy, post-traumatic and MS-related pain) show a modest analgesic effect, with number-needed-to-treat estimates in the range of about 5–11 depending on the analysis [4][5]. TN was not specifically studied in these trials, so this is extrapolation Weak / limited.
Nabiximols (THC:CBD oromucosal spray, Sativex). Approved in several countries for MS-related spasticity and studied in central and peripheral neuropathic pain [6]. A small subset of TN patients have MS-related ("secondary") TN, and there are case reports of benefit in this population Weak / limited.
Adjunctive use alongside carbamazepine. Some case reports describe patients reducing breakthrough attacks when adding inhaled or oromucosal cannabis to existing anticonvulsant therapy [7] Anecdote. Case reports are hypothesis-generating, not proof.
Mechanistic plausibility. Endocannabinoid signaling modulates trigeminal nociception in rodent models of TN-like pain, including infraorbital nerve constriction models [3] [evidence:weak — preclinical only].
What doesn't work, or has weak evidence
CBD-only products for classical TN. Despite heavy marketing, there is no controlled evidence that isolate CBD treats TN No data. CBD has anticonvulsant properties in specific epilepsy syndromes [8], and people sometimes assume that translates to TN (which is sometimes loosely called a "neuralgic seizure" of the nerve). It doesn't follow. Don't assume.
Topical cannabinoid creams on the face. No published evidence in TN No data. The pain generator in classical TN is typically a vascular loop compressing the nerve root entry zone inside the skull — a topical agent has no plausible route to that site.
"Indica strains" for nerve pain. The indica/sativa label does not reliably predict chemistry or clinical effect [9]. Choose by cannabinoid and terpene content if you choose at all, not by marketing category.
High-dose THC alone. Higher doses tend to increase side effects (sedation, dysphoria, tachycardia) without proportionally improving analgesia in neuropathic pain trials [4][5] Weak / limited.
What we don't know
- Whether cannabis reduces attack frequency in classical TN over months, not just acute pain intensity.
- Whether CBD-dominant preparations have any meaningful effect on TN.
- Optimal THC:CBD ratio, dose, or route of administration.
- Whether cannabis helps the dull, constant aching pain of "TN type 2" (atypical TN) more or less than the paroxysmal stabbing pain of TN type 1.
- Long-term effects of daily cannabis use on TN progression, central sensitization, or anticonvulsant efficacy.
There are essentially no adequately powered randomized trials in TN. Until those exist, anyone telling you cannabis definitely works — or definitely doesn't — for TN is overreaching.
Comparison with standard treatments
Carbamazepine is the established first-line treatment. Response rates of 70–80% in classical TN are reported, though tolerability is often the limiting factor [1][2]. Oxcarbazepine has a somewhat better side effect profile with similar efficacy [1].
Microvascular decompression (MVD) is the surgical gold standard for classical TN caused by vascular compression, with long-term pain freedom in roughly 70% of patients at 10 years in experienced hands [2]. Gamma knife radiosurgery and percutaneous procedures (balloon compression, glycerol rhizolysis, radiofrequency rhizotomy) are alternatives for non-surgical candidates [2].
Cannabis has nothing close to this evidence base for TN. If your TN is responsive to carbamazepine or you're a surgical candidate, those are the interventions with actual data. Cannabis is reasonably considered as adjunctive therapy for residual pain or breakthrough attacks, after a real diagnostic workup.
Risks and interactions
Drug interactions matter here. Carbamazepine is a potent inducer of CYP3A4 and can lower plasma THC and CBD levels; conversely, high-dose CBD can inhibit CYP enzymes and raise levels of some anticonvulsants [8][10] [evidence:strong for the interaction in principle, weak for clinical magnitude in TN patients specifically]. Do not change either medication without medical supervision.
Cognitive and motor effects. THC impairs attention, reaction time, and driving performance, especially in occasional users and at higher doses [11]. TN patients are often already sedated by anticonvulsants — stacking can be significant.
Cannabis hyperalgesia / tolerance. Heavy daily use can produce tolerance and, in some chronic pain patients, paradoxical worsening of pain sensitivity. The data are mixed but worth knowing about Disputed.
Cannabinoid hyperemesis, cardiovascular events, and psychiatric effects. Standard cannabis risks apply and are covered in our Risks of Cannabis Use article.
Most important risk: using cannabis as a reason to delay or avoid a proper TN workup. TN can be the first symptom of multiple sclerosis or, rarely, a posterior fossa tumor [1]. Get the MRI.
Sources
- Peer-reviewed Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. European Journal of Neurology. 2019;26(6):831-849.
- Peer-reviewed Cruccu G, Di Stefano G, Truini A. Trigeminal Neuralgia. New England Journal of Medicine. 2020;383(8):754-762.
- Peer-reviewed Liang YC, Huang CC, Hsu KS. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology. 2007;53(1):169-177.
- Peer-reviewed Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2018;3(3):CD012182.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
- Peer-reviewed Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1-3):210-220.
- Peer-reviewed Liang YC, Hsu KS. Therapeutic potential of cannabinoids in trigeminal neuralgia (review of case literature). Current Drug Targets - CNS & Neurological Disorders. 2006;5(5):507-514.
- Peer-reviewed Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017;376(21):2011-2020.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. 2022;17(5):e0267498.
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Hartman RL, Huestis MA. Cannabis effects on driving skills. Clinical Chemistry. 2013;59(3):478-492.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Neuropathic Pain — What the evidence actually says about using cannabis to treat nerve pain, by condition and...